







Marine Genetic Resources (MGRs)



Widely used in pharmaceutics: deep-sea sponges

- <u>What</u>: any material of marine plant, animal, microbial or other origin containing functional units of heredity
- Why: Used in pharmaceutics, cosmetics, biotechnology, etc. -> (Could) have (significant) economic value
- <u>With what goal</u>: Fair and equitable sharing of benefits arising from activities with respect to marine genetic resources and **digital sequence information** (Art. 7)
- How? -> next slides
- Main take-aways: flexible mechanism, all benefits flow to the implementation of BBNJ: conservation, sustainable use & capacity-building









How I: key provisions

Article 10. Notifications for:

- Pre cruise
- Post cruise
- Data-management plan
- BBNJ standardized batch identifier
- Uploading of data on open access database
- Results of utilization: publications, patents, products

Obligations for researchers/companies

Taking into account international practice

Article 11.2. Non-monetary benefit-sharing:

- Access to samples & collections & digital sequence databases
- Participation in research cruises and projects

Article 11.5. Monetary benefisharing:

- 1. Decoupled fee to special fund
- To be replaced by: payments related to commercialization (depending on CBD's DSI modalities)

For conservation & capacity building










How II: governance mechanism











Assessment

Solutions		Challenges
+	guaranteeing benefit-sharing consisting of access, participation & monetary benefits related to commercialization (G77 demanded no hand-out but right to commercially oriented fee) Bala	- some notification/reporting burden for researchers & companies (EU + likeminded wanted to avoid burdensome track & trace)
+	all monetary benefits for the implementation of BBNJ: conservation, sustainable use & capacity-building	 can it include private multi-national companies? Many "where practicable" Incentives
+	flexible: future system & inclusion of DSI can be harmonized with global benefit-sharing system under CBD	- still, DSI issue likely to politicize COP decisions









Questions?

Arne Langlet ERC Project MARIPOLDATA University of Vienna arne.langlet@univie.ac.at